Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVATAR: Immunological analysis of ex vivo tofacitinib-treated biopsies to predict response in ulcerative colitis
2018-004890-28Phase 4Active
- Sponsor
- University of Rome Tor Vergata, Department of Systems Medicine
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of tofacitinib in autoimmune colitis, sponsored by University of Rome Tor Vergata, Department of Systems Medicine. Started Oct 2020; status: active.
02
Drugs
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2018-004890-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004890-28.